Angela Romero, MD
Family Medicine · Albuquerque, NMNPI 1699757187
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,204 and has fallen 98.4% since, to $19 in 2025. Among family medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$640
- AstraZeneca$580
- Watermark Medical, Inc.$513
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$461
- Pfizer$443
- AbbVie$424
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,16799%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 48 | $640 |
| AstraZeneca | 36 | $580 |
| Watermark Medical, Inc. | 1 | $513 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $461 |
| Pfizer | 25 | $443 |
| AbbVie(2 entities) | 27 | $424 |
| Indivior Inc. | 17 | $259 |
| Boehringer Ingelheim | 13 | $253 |
| E.r. Squibb & Sons, L.L.C. | 9 | $156 |
| Exact Sciences | 6 | $120 |
| Novo Nordisk | 7 | $119 |
| Amgen | 7 | $113 |
| GSK | 7 | $102 |
| Amarin Pharma, Inc. | 5 | $97 |
| Johnson & Johnson | 5 | $93 |
| Novartis | 6 | $89 |
| Myriad Women's Health, Inc. | 1 | $78 |
| Teva Pharmaceuticals USA, Inc. | 4 | $78 |
| Alkermes, Inc. | 3 | $55 |
| Biohaven Pharmaceuticals, Inc. | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 3 | $51 |
| Bayer | 3 | $49 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Braeburn Inc. | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Sanofi Pasteur Inc. | 2 | $35 |
| Merck | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Angiodynamics, Inc. | 1 | $25 |
| Gilead | 1 | $24 |
| Astellas Pharma US Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Abbott | 1 | $12 |
How this compares
$5,221 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 70 | $77,412 |
| EliquisApixaban | 83 | $73,313 |
| OzempicSemaglutide | 48 | $58,252 |
| JanuviaSitagliptin Phosphate | 33 | $43,844 |
| LinzessLinaclotide | 51 | $39,480 |
| FarxigaDapagliflozin Propanediol | 45 | $38,680 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $23,097 |
| XareltoRivaroxaban | 14 | $21,426 |
| MounjaroTirzepatide | 18 | $19,353 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $19,061 |
| Spiriva RespimatTiotropium Bromide | 21 | $15,320 |
| MyrbetriqMirabegron | 17 | $15,177 |
| InvokanaCanagliflozin | 21 | $14,770 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $13,511 |
| Spiriva HandihalerTiotropium Bromide | 22 | $10,844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $640 | $96,76588 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $580 | $80,837127 claims |
| PfizerEliquis | $443 | $73,31383 claims |
| Novo NordiskOzempic | $119 | $58,25248 claims |
| MerckJanuvia, Janumet | $32 | $57,35545 claims |
| AbbVieLinzess | $424 | $39,48051 claims |
| Johnson & JohnsonXarelto, Invokana | $93 | $36,19635 claims |
| Boehringer IngelheimSpiriva Respimat | $253 | $15,32021 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $15,17717 claims |
| Indivior Inc.Suboxone | $259 | $9,04513 claims |
| Sanofi-aventis U.S. LLCLantus | $31 | $4,23518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Albuquerque
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
- Timothy GrenemyerAlbuquerque$10K
- Cheri BlackstenAlbuquerque$9K
- Michael MontoyaAlbuquerque$7K
- Yvonne Vanarsdale-ImaniAlbuquerque$7K
- Donald OrtizAlbuquerque$7K
- Satkirin KhalsaAlbuquerque$6K
- H Preston MatthewsAlbuquerque$5K
- John StuartAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.